Yves Pommier

List of Publications by Citations

252 papers	22,781 citations	74 h-index	147 g-index
283 ext. papers	26,307 ext. citations	10.9 avg, IF	7.29 L-index

#	Paper	IF	Citations
252	Topoisomerase I inhibitors: camptothecins and beyond. *Nature Reviews Cancer*, **2006**, 6, 789-802	31.3	1510
251	DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. *Chemistry and Biology*, **2010**, 17, 421-33		1233
250	GammaH2AX and cancer. *Nature Reviews Cancer*, **2008**, 8, 957-67	31.3	1216
249	Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. *Cancer Research*, **2012**, 72, 5588-99	10.1	1186
248	A gene expression database for the molecular pharmacology of cancer. *Nature Genetics*, **2000**, 24, 236-44	36.3	1173
247	Drugging topoisomerases: lessons and challenges. *ACS Chemical Biology*, **2013**, 8, 82-95	4.9	569
246	Integrase inhibitors to treat HIV/AIDS. *Nature Reviews Drug Discovery*, **2005**, 4, 236-48	64.1	549
245	DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. *Chemical Reviews*, **2009**, 109, 2894-902	68.1	524
244	Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. *Oncogene*, **2004**, 23, 2934-49	9.2	475
243	Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. *Nature Reviews Molecular Cell Biology*, **2016**, 17, 703-721	48.7	461
242	Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. *Molecular Cancer Therapeutics*, **2014**, 13, 433-43	6.1	459
241	Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. *Journal of Medicinal Chemistry*, **2005**, 48, 2336-45	8.3	373
240	Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. *Nature Cell Biology*, **2009**, 11, 1315-24	23.4	351
239	Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. *Science Translational Medicine*, **2016**, 8, 362ps17	17.5	343
238	Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. *Nature Medicine*, **2001**, 7, 961-6	50.5	290
237	Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. *Molecular and Cellular Biology*, **2000**, 20, 3977-87	4.8	280
236	DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. *Biochemistry*, **1996**, 35, 13303-9	3.2	265

235	A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. *Nature Medicine*, **2017**, 23, 461-471	50.5	253
234	Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. *Science*, **2011**, 332, 1561-4	33.3	215
233	Repair of topoisomerase I-mediated DNA damage. *Progress in Molecular Biology and Translational Science*, **2006**, 81, 179-229		213
232	Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. *Journal of Medicinal Chemistry*, **1997**, 40, 3057-63	8.3	210
231	The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. *Cancer Research*, **2013**, 73, 4372-82	10.1	207
230	Genome Organization Drives Chromosome Fragility. *Cell*, **2017**, 170, 507-521.e18	56.2	203
229	Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). *DNA Repair*, **2014**, 19, 114-29	4.3	192
228	Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. *Cancer Investigation*, **1994**, 12, 530-42	2.1	190
227	Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 349, 408-16	4.7	179
226	Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 15030-5	11.5	179
225	Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. *EMBO Reports*, **2009**, 10, 887-93	6.5	176
224	Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. *Nucleic Acids Research*, **1990**, 18, 6611-9	20.1	169
223	Interfacial inhibitors: targeting macromolecular complexes. *Nature Reviews Drug Discovery*, **2011**, 11, 25-36	64.1	166
222	Topoisomerase I-mediated DNA damage. *Advances in Cancer Research*, **2001**, 80, 189-216	5.9	166
221	CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. *BMC Genomics*, **2009** , 10, 277	4.5	165
220	Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. *Journal of Medicinal Chemistry*, **2001**, 44, 3254-63	8.3	159
219	Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. *Oncotarget*, **2016**, 7, 76534-76550	3.3	154
218	Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. *Journal of Biological Chemistry*, **1999**, 274, 8516-23	5.4	153

217	Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. *Trends in Pharmacological Sciences*, **2005**, 26, 138-45	13.2	147
216	Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. *Journal of Biological Chemistry*, **1997**, 272, 7792-6	5.4	146
215	RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription. *Cell*, **2016**, 165, 357-71	56.2	142
214	Topoisomerase I inhibitors: selectivity and cellular resistance. *Drug Resistance Updates*, **1999**, 2, 307-318	23.2	141
213	PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. *Nucleic Acids Research*, **2014**, 42, 4435-49	20.1	139
212	Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. *Journal of Biological Chemistry*, **1997**, 272, 26441-7	5.4	137
211	Ion selective folding of loop domains in a potent anti-HIV oligonucleotide. *Biochemistry*, **1997**, 36, 12498-505	3.2	132
210	Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. *Nucleic Acids Research*, **1991**, 19, 5973-80	20.1	131
209	Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells. *Journal of Biological Chemistry*, **2012**, 287, 12848-57	5.4	130
208	The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. *Molecular Cancer Therapeutics*, **2009**, 8, 1008-14	6.1	124
207	The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. *Journal of Medicinal Chemistry*, **2000**, 43, 3970-80	8.3	124
206	Mechanisms of camptothecin resistance by human topoisomerase I mutations. *Journal of Molecular Biology*, **2004**, 339, 773-84	6.5	121
205	Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. *Journal of Cell Biology*, **2011**, 195, 739-49	7.3	120
204	Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. *Journal of Medicinal Chemistry*, **1999**, 42, 446-57	8.3	118
203	SLFN11 Blocks Stressed Replication Forks Independently of ATR. *Molecular Cell*, **2018**, 69, 371-384.e6	17.6	115
202	Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. *Anti-Cancer Agents in Medicinal Chemistry*, **2008**, 8, 381-9	2.2	113
201	Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. *Nucleic Acids Research*, **2011**, 39, 3607-20	20.1	111
200	ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. *Cancer Research*, **2014**, 74, 6968-79	10.1	110

199	Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA-PK. *EMBO Journal*, **2009**, 28, 3667-80	13	110
198	Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 19790-5	11.5	107
197	Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. *Nucleic Acids Research*, **2002**, 30, 1198-204	20.1	102
196	Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. *Journal of Medicinal Chemistry*, **2005**, 48, 4803-14	8.3	97
195	Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. *International Journal of Cancer*, **1999**, 82, 396-404	7.5	97
194	Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel. *Molecular Cancer Therapeutics*, **2014**, 13, 214-20	6.1	96
193	Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. *Journal of Biological Chemistry*, **2009**, 284, 18085-95	5.4	96
192	Targeting Topoisomerase I in the Era of Precision Medicine. *Clinical Cancer Research*, **2019**, 25, 6581-6589	12.9	89
191	Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity. *Molecular Cell*, **2019**, 75, 252-266.e8	17.6	89
190	Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. *Oncotarget*, **2016**, 7, 3084-97	3.3	88
189	DNA cleavage assay for the identification of topoisomerase I inhibitors. *Nature Protocols*, **2008**, 3, 1736-50	18.8	85
188	Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2‐DNA and Top2‐RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2). *Journal of Biological Chemistry*, **2014**, 289, 17960-9	5.4	84
187	Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. *Cancer Research*, **2007**, 67, 8752-61	10.1	84
186	Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. *Clinical Cancer Research*, **2014**, 20, 4873-81	12.9	81
185	Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. *Anti-Cancer Agents in Medicinal Chemistry*, **2004**, 4, 429-34		78
184	CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. *IScience*, **2018**, 10, 247-264	6.1	78
183	Chk2 molecular interaction map and rationale for Chk2 inhibitors. *Clinical Cancer Research*, **2006**, 12, 2657-61	12.9	76
182	TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs. *Nucleic Acids Research*, **2013**, 41, 7793-803	20.1	75

181	Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. *Leukemia and Lymphoma*, **1994**, 15, 21-32	1.9	75
180	Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors. *Journal of Medicinal Chemistry*, **2012**, 55, 4457-78	8.3	74
179	Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. *Oncogene*, **2001**, 20, 1852-9	9.2	74
178	Production of Extrachromosomal MicroDNAs Is Linked to Mismatch Repair Pathways and Transcriptional Activity. *Cell Reports*, **2015**, 11, 1749-59	10.6	72
177	TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1. *Nucleic Acids Research*, **2012**, 40, 8371-80	20.1	71
176	Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism. *PLoS ONE*, **2012**, 7, e41094	3.7	70
175	Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors. *Expert Opinion on Therapeutic Patents*, **2011**, 21, 1285-92	6.8	68
174	Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. *Clinical Cancer Research*, **2002**, 8, 2499-504	12.9	68
173	8-Oxoguanine rearranges the active site of human topoisomerase I. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 12102-7	11.5	67
172	SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. *Clinical Cancer Research*, **2015**, 21, 4184-93	12.9	65
171	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. *Pharmacology & Therapeutics*, **2019**, 201, 94-102	13.9	63
170	Temozolomide in the Era of Precision Medicine. *Cancer Research*, **2017**, 77, 823-826	10.1	61
169	Interfacial inhibitors of protein-nucleic acid interactions. *Anti-Cancer Agents in Medicinal Chemistry*, **2005**, 5, 421-9		60
168	Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype. *PLoS ONE*, **2014**, 9, e99269	3.7	58
167	Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. *FEBS Letters*, **2001**, 505, 7-12	3.8	56
166	Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. *Cancer Chemotherapy and Pharmacology*, **1997**, 40, 433-8	3.5	54
165	Dual Processing of R-Loops and Topoisomerase I Induces Transcription-Dependent DNA Double-Strand Breaks. *Cell Reports*, **2019**, 28, 3167-3181.e6	10.6	53
164	Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors. *Annals of the New York Academy of Sciences*, **2000**, 922, 11-26	6.5	53

163	Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase II in reconstituted simian virus 40 chromatin. *Nucleic Acids Research*, **1990**, 18, 4553-9	20.1	52
162	Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. *PLoS ONE*, **2017**, 12, e0171582	3.7	51
161	Increased negative supercoiling of mtDNA in TOP1mt knockout mice and presence of topoisomerases IIIand IIIn vertebrate mitochondria. *Nucleic Acids Research*, **2014**, 42, 7259-67	20.1	51
160	Biochemical characterization of human tyrosyl-DNA phosphodiesterase 2 (TDP2/TTRAP): a Mg(2+)/Mn(2+)-dependent phosphodiesterase specific for the repair of topoisomerase cleavage complexes. *Journal of Biological Chemistry*, **2012**, 287, 30842-52	5.4	50
159	Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. *Clinical Cancer Research*, **2015**, 21, 3841-52	12.9	49
158	Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. *Journal of Molecular Biology*, **2008**, 381, 540-9	6.5	49
157	Structural basis for recognition of 5Qphosphotyrosine adducts by Tdp2. *Nature Structural and Molecular Biology*, **2012**, 19, 1372-7	17.6	48
156	Topoisomerase I-mediated cleavage at unrepaired ribonucleotides generates DNA double-strand breaks. *EMBO Journal*, **2017**, 36, 361-373	13	46
155	Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. *DNA Repair*, **2015**, 28, 107-15	4.3	44
154	DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. *Mutation Research DNA Repair*, **1995**, 337, 135-45		44
153	RNA topoisomerase is prevalent in all domains of life and associates with polyribosomes in animals. *Nucleic Acids Research*, **2016**, 44, 6335-49	20.1	44
152	Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors. *Journal of Medicinal Chemistry*, **2015**, 58, 3188-208	8.3	43
151	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. *Science Translational Medicine*, **2020**, 12,	17.5	43
150	Topoisomerase I alone is sufficient to produce short DNA deletions and can also reverse nicks at ribonucleotide sites. *Journal of Biological Chemistry*, **2015**, 290, 14068-76	5.4	43
149	Poisoning of mitochondrial topoisomerase I by lamellarin D. *Molecular Pharmacology*, **2014**, 86, 193-9	4.3	43
148	MGMT Status as a Clinical Biomarker in Glioblastoma. *Trends in Cancer*, **2020**, 6, 380-391	12.5	43
147	Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (Expression with Class I Histone Deacetylase Inhibitors. *Clinical Cancer Research*, **2018**, 24, 1944-1953	12.9	42
146	DNA double-strand breaks and ATM activation by transcription-blocking DNA lesions. *Cell Cycle*, **2010**, 9, 274-8	4.7	42

145	A kinetic clutch governs religation by type IB topoisomerases and determines camptothecin sensitivity. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 16125-30	11.5	41
144	Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex. *Journal of Biological Chemistry*, **2003**, 278, 12461-6	5.4	39
143	Relative contribution of four nucleases, CtIP, Dna2, Exo1 and Mre11, to the initial step of DNA double-strand break repair by homologous recombination in both the chicken DT40 and human TK6 cell lines. *Genes To Cells*, **2015**, 20, 1059-76	2.3	38
142	Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2). *Journal of Medicinal Chemistry*, **2017**, 60, 3275-3288	8.3	37
141	Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 11282-7	11.5	37
140	Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2). *Journal of Medicinal Chemistry*, **2016**, 59, 2734-46	8.3	37
139	The NCI-60 Methylome and Its Integration into CellMiner. *Cancer Research*, **2017**, 77, 601-612	10.1	34
138	Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore. *Journal of Medicinal Chemistry*, **2015**, 58, 3997-4015	8.3	34
137	PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes. *Nucleic Acids Research*, **2018**, 46, 5601-5617	20.1	33
136	Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site. *Journal of Biological Chemistry*, **2002**, 277, 13666-72	5.4	33
135	The evolving landscape of predictive biomarkers of response to PARP inhibitors. *Journal of Clinical Investigation*, **2018**, 128, 1727-1730	15.9	32
134	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. *Cell Reports*, **2020**, 33, 108296	10.6	32
133	Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC). *DNA Repair*, **2020**, 89, 102837	4.3	31
132	High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. *PLoS ONE*, **2014**, 9, e92047	3.7	31
131	Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer. *Oncotarget*, **2016**, 7, 13269-84	3.3	31
130	rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R. *Bioinformatics*, **2016**, 32, 1272-4	7.2	30
129	Thirteen-exon-motif signature for vertebrate nuclear and mitochondrial type IB topoisomerases. *Nucleic Acids Research*, **2004**, 32, 2087-92	20.1	30
128	Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate. *Journal of Biological Chemistry*, **2000**, 275, 15246-53	5.4	30

127	Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. *Nucleic Acids Research*, **1999**, 27, 1919-25	20.1	30
126	Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. *Journal of Medicinal Chemistry*, **2018**, 61, 9908-9930	8.3	30
125	N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase. *Journal of Medicinal Chemistry*, **2015**, 58, 4610-23	8.3	29
124	Negative regulation of mitochondrial transcription by mitochondrial topoisomerase I. *Nucleic Acids Research*, **2013**, 41, 9848-57	20.1	29
123	A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation. *Science Advances*, **2020**, 6,	14.3	29
122	HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases. *ACS Chemical Biology*, **2016**, 11, 1074-81	4.9	27
121	Interfacial inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 3961-5	2.9	26
120	Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. *Journal of Thoracic Oncology*, **2020**, 15, 843-859	8.9	26
119	NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. *Clinical Cancer Research*, **2018**, 24, 5830-5840	12.9	26
118	Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 7315-7332	8.3	26
117	Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. *Oncotarget*, **2016**, 7, 13984-4001	3.3	26
116	Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons. *Journal of Medicinal Chemistry*, **2016**, 59, 3840-53	8.3	26
115	Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400). *Journal of Medicinal Chemistry*, **2016**, 59, 4890-9	8.3	26
114	Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I. *Journal of Medicinal Chemistry*, **2017**, 60, 5364-5376	8.3	25
113	ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair. *PLoS ONE*, **2017**, 12, e0188320	3.7	25
112	Small cell lung cancer: Time to revisit DNA-damaging chemotherapy. *Science Translational Medicine*, **2016**, 8, 346fs12	17.5	24
111	How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair?. *Cell Biochemistry and Biophysics*, **2000**, 33, 175-80	3.2	24
110	Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter elution assay. *Drug Development Research*, **1995**, 34, 138-144	5.1	24

109	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. *Cancer Cell*, **2021**, 39, 566-579.e7	24.3	24
108	Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, **2016**, 78, 73-81	3.5	24
107	Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. *Oncogene*, **2019**, 38, 180-193	9.2	23
106	Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. *DNA Repair*, **2014**, 13, 1-9	4.3	23
105	TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors. *Molecular Cancer Therapeutics*, **2017**, 16, 2543-2551	6.1	23
104	In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. *Nucleic Acids Research*, **1997**, 25, 4111-6	20.1	23
103	Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. *Pharmaceutical Research*, **1996**, 13, 1892-5	4.5	23
102	Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2. *ACS Chemical Biology*, **2016**, 11, 1925-33	4.9	23
101	Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. *Molecular Cancer Therapeutics*, **2018**, 17, 1694-1704	6.1	22
100	Debulking of topoisomerase DNA-protein crosslinks (TOP-DPC) by the proteasome, non-proteasomal and non-proteolytic pathways. *DNA Repair*, **2020**, 94, 102926	4.3	22
99	Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress. *Cell Reports*, **2020**, 30, 4137-4151.e6	10.6	21
98	Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC. *Nucleic Acids Research*, **2011**, 39, 6620-32	20.1	21
97	Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant gene associated with Angelman syndrome. *Molecular Autism*, **2018**, 9, 45	6.5	19
96	The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib. *Clinical Cancer Research*, **2019**, 25, 6206-6216	12.9	19
95	Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. *Clinical Cancer Research*, **2017**, 23, 2116-2126	12.9	19
94	Cellular resistance to camptothecins. *Annals of the New York Academy of Sciences*, **1996**, 803, 60-73	6.5	19
93	Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening. *Nucleic Acids Research*, **2019**, 47, 10134-10150	20.1	18
92	Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 1469-79	3.4	18

91	Role of a tryptophan anchor in human topoisomerase I structure, function and inhibition. *Biochemical Journal*, **2008**, 411, 523-30	3.8	18
90	Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. *Journal of Experimental and Clinical Cancer Research*, **2016**, 35, 56	12.8	18
89	Biochemical assays for the discovery of TDP1 inhibitors. *Molecular Cancer Therapeutics*, **2014**, 13, 2116-26	6.1	17
88	Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes. *ACS Chemical Biology*, **2016**, 11, 2996-3001	4.9	17
87	Mapping topoisomerase sites in mitochondrial DNA with a poisonous mitochondrial topoisomerase I (Top1mt). *Journal of Biological Chemistry*, **2014**, 289, 18595-602	5.4	16
86	Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. *DNA Repair*, **2014**, 21, 177-82	4.3	16
85	Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors. *European Journal of Medicinal Chemistry*, **2015**, 101, 525-33	6.8	15
84	Chromatin Regulators as a Guide for Cancer Treatment Choice. *Molecular Cancer Therapeutics*, **2016**, 15, 1768-77	6.1	15
83	Neuroprotection and repair of 3′ blocking DNA ends by glaikit (gkt) encoding Drosophila tyrosyl-DNA phosphodiesterase 1 (TDP1). *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 15816-20	11.5	15
82	Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. *International Journal of Cancer*, **1994**, 58, 85-94	7.5	15
81	Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer. *Oncogene*, **2020**, 39, 5520-5535	9.2	15
80	Novel TDP2-ubiquitin interactions and their importance for the repair of topoisomerase II-mediated DNA damage. *Nucleic Acids Research*, **2016**, 44, 10201-10215	20.1	15
79	DNA-Targeted Precision Medicine; Have we Been Caught Sleeping?. *Trends in Cancer*, **2017**, 3, 2-6	12.5	14
78	Biological evaluation of imidazolium- and ammonium-based salts as HIV-1 integrase inhibitors. *MedChemComm*, **2011**, 2, 143-150	5	14
77	Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. *International Journal of Cancer*, **1995**, 63, 268-75	7.5	14
76	The dominant role of proofreading exonuclease activity of replicative polymerase δ in cellular tolerance to cytarabine (Ara-C). *Oncotarget*, **2017**, 8, 33457-33474	3.3	14
75	Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity. *European Journal of Medicinal Chemistry*, **2021**, 215, 113261	6.8	14
74	Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 478, 569-579	5.1	14

73	Genomic and evolutionary classification of lung cancer in never smokers. *Nature Genetics*, **2021**, 53, 1348-1359	36.3	14
72	Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription. *Journal of Biological Chemistry*, **2017**, 292, 20162-20172	5.4	13
71	Mitochondrial tyrosyl-DNA phosphodiesterase 2 and its TDP2 short isoform. *EMBO Reports*, **2018**, 19,	6.5	12
70	Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides. *European Journal of Pharmaceutical Sciences*, **2018**, 111, 337-348	5.1	12
69	Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors. *Frontiers in Oncology*, **2019**, 9, 994	5.3	12
68	Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1). *SLAS Discovery*, **2017**, 22, 1093-1105	3.4	12
67	Parallel analysis of ribonucleotide-dependent deletions produced by yeast Top1 in vitro and in vivo. *Nucleic Acids Research*, **2016**, 44, 7714-21	20.1	12
66	Selectivity for strand-transfer over 3′-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site. *Nucleic Acids Research*, **2016**, 44, 6896-906	20.1	12
65	New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2). *European Journal of Pharmaceutical Sciences*, **2018**, 118, 67-79	5.1	11
64	TDP1 suppresses mis-joining of radiomimetic DNA double-strand breaks and cooperates with Artemis to promote optimal nonhomologous end joining. *Nucleic Acids Research*, **2018**, 46, 8926-8939	20.1	11
63	Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. *Marine Drugs*, **2015**, 13, 3625-39	6	11
62	Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors. *Molecular Cancer Therapeutics*, **2015**, 14, 2552-9	6.1	11
61	Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. *Cancer Chemotherapy and Pharmacology*, **2000**, 45, 409-16	3.5	11
60	SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	11
59	The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy. *BMC Cancer*, **2020**, 20, 1123	4.8	10
58	Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. *Molecular Cancer Therapeutics*, **2021**, 20, 1431-1441	6.1	10
57	F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death. *Future Oncology*, **2016**, 12, 2183-8	3.6	9
56	Early Induction of Apoptosis in Hematopoietic Cell Lines After Exposure to Flavopiridol. *Blood*, **1998**, 91, 458-465	2.2	9

55	Multiview confocal super-resolution microscopy. *Nature*, **2021**, 600, 279-284	50.4	9
54	HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia. *Scientific Reports*, **2017**, 7, 12849	4.9	8
53	Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. *European Journal of Medicinal Chemistry*, **2019**, 178, 81-92	6.8	8
52	Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide. *Journal of Medicinal Chemistry*, **2019**, 62, 4669-4682	8.3	8
51	Topoisomerase I-driven repair of UV-induced damage in NER-deficient cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 14412-14420	11.5	8
50	SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. *Cancer Research*, **2021**, 81, 3067-3078	10.1	8
49	Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series. *Journal of Medicinal Chemistry*, **2018**, 61, 10440-10462	8.3	8
48	Beyond the unwinding: role of TOP1MT in mitochondrial translation. *Cell Cycle*, **2019**, 18, 2377-2384	4.7	7
47	Anti-HIV-1 activity of a tripodal receptor that recognizes mannose oligomers. *European Journal of Medicinal Chemistry*, **2015**, 106, 132-43	6.8	7
46	DNA Topoisomerases and Their Inhibition by Anthracyclines. *ACS Symposium Series*, **1994**, 183-203	0.4	7
45	The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.. *Nature Cell Biology*, **2022**,	23.4	7
44	Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer. *Journal of Medicinal Chemistry*, 2021, 64, 7617-7629	8.3	7
43	An interplay of NOX1-derived ROS and oxygen determines the spermatogonial stem cell self-renewal efficiency under hypoxia. *Genes and Development*, **2021**, 35, 250-260	12.6	7
42	Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites. *Chemical Science*, **2021**, 12, 3876-3884	9.4	7
41	Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development. *PLoS ONE*, **2021**, 16, e0237554	3.7	7
40	Human topoisomerases and their roles in genome stability and organization.. *Nature Reviews Molecular Cell Biology*, **2022**,	48.7	7
39	Virtual screening using ligand-based pharmacophores for inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1). *Bioorganic and Medicinal Chemistry*, **2010**, 18, 2347-2355	3.4	6
38	BAMscale: quantification of next-generation sequencing peaks and generation of scaled coverage tracks. *Epigenetics and Chromatin*, **2020**, 13, 21	5.8	6

37	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. *Science Translational Medicine*, **2021**, 13,	17.5	6
36	Effects of camptothecin or TOP1 overexpression on genetic stability in Saccharomyces cerevisiae. *DNA Repair*, **2017**, 59, 69-75	4.3	5
35	The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2. *Molecular Cancer Therapeutics*, **2020**, 19, 1589-1597	6.1	5
34	Endogenous single-strand DNA breaks at RNA polymerase II promoters in Saccharomyces cerevisiae. *Nucleic Acids Research*, **2018**, 46, 10649-10668	20.1	5
33	A conserved SUMO-Ubiquitin pathway directed by RNF4/SLX5-SLX8 and PIAS4/SIZ1 drives proteasomal degradation of topoisomerase DNA-protein crosslinks		5
32	Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. *DNA Repair*, **2020**, 85, 102747	4.3	5
31	Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I. *Journal of the American Chemical Society*, **2020**, 142, 21178-21188	16.4	5
30	Mammalian Tyrosyl-DNA Phosphodiesterases in the Context of Mitochondrial DNA Repair. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	4
29	topIb, a phylogenetic hallmark gene of Thaumarchaeota encodes a functional eukaryote-like topoisomerase IB. *Nucleic Acids Research*, **2016**, 44, 2795-805	20.1	4
28	Distribution bias and biochemical characterization of TOP1MT single nucleotide variants. *Scientific Reports*, **2017**, 7, 8614	4.9	4
27	DNA and RNA Cleavage Complexes and Repair Pathway for TOP3B RNA- and DNA-Protein Crosslinks. *Cell Reports*, **2020**, 33, 108569	10.6	4
26	A polymer index-matched to water enables diverse applications in fluorescence microscopy. *Lab on A Chip*, **2021**, 21, 1549-1562	7.2	4
25	The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2019**, 34, 818-822	5.6	3
24	Rapid proteotyping reveals cancer biology and drug response determinants in the NCI-60 cells		3
23	Probing the evolutionary conserved residues Y204, F259, S400 and W590 that shape the catalytic groove of human TDP1 for 3Qand 5Qphosphodiester-DNA bond cleavage. *DNA Repair*, **2018**, 66-67, 64-71	4.3	3
22	PARylation prevents the proteasomal degradation of topoisomerase I DNA-protein crosslinks and induces their deubiquitylation. *Nature Communications*, **2021**, 12, 5010	17.4	3
21	Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1-DNA complexes. *Nucleic Acids Research*, **2021**, 49, 10493-10506	20.1	3
20	Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening. *Molecules*, **2019**, 24,	4.8	2

19	Mutations in the HIV type 1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to zidovudine. *AIDS Research and Human Retroviruses*, **2000**, 16, 1417-22	1.6	2
18	Novel screen for anti-cancer drugs that elevate chromosome instability (CIN) using human artificial chromosome (HAC). *Oncotarget*, **2018**, 9, 36833-36835	3.3	2
17	Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy. *Cancer Science*, **2021**,	6.9	2
16	2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights.. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2022**, 37, 349-372	5.6	2
15	Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1. *Cancer Research*, **2019**, 79, 2460-2461	10.1	1
14	HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence. *Molecules*, **2018**, 23,	4.8	1
13	Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states.. *Nature Communications*, **2022**, 13, 59	17.4	1
12	Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor. *Molecular Cancer Research*, **2021**, 19, 1338-1349	6.6	1
11	Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. *Cancers*, **2021**, 13,	6.6	1
10	Synthesis of 11-aminoalkoxy substituted benzophenanthridine derivatives as tyrosyl-DNA phosphodiesterase 1 inhibitors and their anticancer activity.. *Bioorganic Chemistry*, **2022**, 123, 105789	5.1	1
9	SUMO: A Swiss Army Knife for Eukaryotic Topoisomerases.. *Frontiers in Molecular Biosciences*, **2022**, 9, 871161	5.6	1
8	Design and synthesis of C-aryl angular luotonins via a one-pot aza-Nazarov-Friedlander sequence and their Topo-I inhibition studies along with C-aryl vasicinones and luotonins. *Bioorganic and Medicinal Chemistry Letters*, **2021**, 41, 127998	2.9	0
7	Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway. *IScience*, **2021**, 24, 103173	6.1	0
6	Cancer/Testis Antigen 55 is required for cancer cell proliferation and mitochondrial DNA maintenance.. *Mitochondrion*, **2022**, 64, 19-26	4.9	0
5	From Antarctica to cancer research: a novel human DNA topoisomerase 1B inhibitor from Antarctic sponge Dendrilla antarctica. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2022**, 37, 1404-1410	5.6	0
4	Bay-Region Diol Epoxides of Benzo[a]Pyrene are Stealth Poisons of Topoisomerase I. *Polycyclic Aromatic Compounds*, **2000**, 21, 53-62	1.3	
3	Functions of the CSB Protein at Topoisomerase 2 Inhibitors-Induced DNA Lesions. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 727836	5.7	
2	Topoisomerase-Induced DNA Cleavage at Ribonucleotide Misincorporation Sites. *FASEB Journal*, **2015**, 29, 371.3	0.9	

1 Response to Letter to the Editor by Yang et al. *Journal of Thoracic Oncology*, **2020**, 15, e91 8.9